Rivopam

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rivopam

What is Rivopam?

Rivopam is a pharmacological agent belonging to the benzodiazepine class of medications. It is primarily characterized by its effects on the central nervous system, where it acts to modify specific chemical activities in the brain. As a psychoactive substance, it is utilized in clinical settings to address conditions related to neurological overactivity.

Mechanism of Action

The therapeutic effects of Rivopam are achieved through its interaction with gamma-aminobutyric acid (GABA) receptors. GABA is the primary inhibitory neurotransmitter in the human brain, responsible for reducing neuronal excitability. By enhancing the efficiency of these receptors, Rivopam facilitates a calming effect on the nervous system, which helps in the management of symptoms associated with various neurological and psychological imbalances.

General Characteristics

Rivopam is recognized for its specific pharmacokinetic profile, including its onset of action and the duration for which it remains active in the body. Like other members of the benzodiazepine family, it is typically identified by its sedative, anxiolytic, and muscle-relaxant properties. Its application is determined by the need to stabilize neural signaling and provide symptomatic relief for patients experiencing acute or chronic episodes of central nervous system hyperexcitability.

Regulatory References

  1. WHO Essential Medicines List - Clonazepam
  2. NIH StatPearls: Clonazepam

What side effects are possible with Rivopam?

Possible Side Effects and Safety Information

The safety profile for Rivopam (Clonazepam) is officially documented based on its classification as a Central Nervous System (CNS) depressant. The most frequently observed adverse reactions are characteristic of this action.

Common and Expected Adverse Reactions

Adverse reactions classified as common in regulatory documents often occur at the start of treatment or during dose escalation and may include:

  • Somnolence (Drowsiness)
  • Ataxia (Impaired Coordination)
  • Dizziness
  • Muscle Weakness and Fatigue

Reactions are grouped by the affected physiological system. For instance, Nervous System Disorders include nystagmus (involuntary eye movement) and slurred speech, while Psychiatric Disorders may involve depression, confusion, and memory impairment.

Serious Safety Considerations

Official labeling emphasizes several serious safety risks, some of which are subject to prominent warnings by government health authorities:

  • Risk of Abuse, Misuse, and Addiction: Use of the medicine can lead to physical dependence.
  • Physical Dependence and Withdrawal: Abrupt cessation may precipitate acute, potentially severe, withdrawal reactions.
  • Respiratory Depression: The risk of profound sedation and severely slowed breathing is increased when used concomitantly with other CNS depressants, such as opioids.
  • Paradoxical Reactions: Psychiatric disturbances such as agitation, aggression, and hostility may occur.

Population-Specific Notes and Restrictions

Regulatory documents include specific considerations for certain patient groups. Older adults are noted as more susceptible to confusion and severe drowsiness, which can increase the risk of falls. The medicine is contraindicated in individuals with a known hypersensitivity to benzodiazepines or with clinical evidence of severe liver disease. Common effects are often more pronounced at the initiation of treatment and risks like dependence are associated with long-term exposure.

Overdose and Emergency Response

Rivopam overdose manifestations are strictly defined by regulatory authorities as a spectrum of Central Nervous System (CNS) depression. Documented signs include somnolence, mental confusion, ataxia (impaired coordination), and diminished reflexes.

The official documentation emphasizes the potential for severe or life-threatening outcomes, specifically respiratory depression, coma, and hypotension. The risk of these adverse events, including death, is significantly increased in cases of co-ingestion, particularly with other CNS depressants such as alcohol or opioids.

Immediate medical attention is required for any suspected overdose. Regulatory guidance mandates that emergency services must be contacted immediately if the individual is unresponsive, has severely slowed or stopped breathing, or has collapsed.

Management is primarily symptomatic and supportive, focusing on securing a clear airway and ensuring adequate ventilation. While the antagonist Flumazenil is available to reverse sedative effects, its use is associated with a specific regulatory warning: it is generally not indicated in patients with epilepsy due to the documented risk of precipitating seizures. Furthermore, elderly patients and those with severe chronic obstructive airways disease or hepatic impairment are noted in official labeling to be at higher risk for more serious respiratory depressant effects.

Therapeutic Uses of Rivopam

What Rivopam treats: main uses and benefits

Rivopam is a prescription medication commonly used to help manage symptoms related to increased neurological or muscular activity across several key therapeutic domains. It is relevant in clinical settings where symptoms are characterized by intensity, recurrence, or functional disruption. The medication is commonly used to help control certain types of seizures and to treat panic attacks. It may be part of symptomatic management in contexts involving heightened physiological or emotional tension.

Controlling Severe Seizure Disorders

This domain plays a role in managing the medication's primary anti-convulsive benefit for various types of epilepsy. It is applied in situations involving symptoms of increased neurological activity that lead to recurrent, uncontrolled movements or disturbances of consciousness, such as myoclonic seizures, absence seizures, and conditions like Lennox-Gastaut syndrome. The medicine is relevant for easing these pronounced symptoms, which may support the patient during difficult episodes.

Quick Fact: Relief for Involuntary Neurological Surges


Easing Acute Panic Attacks and Intense Anxiety

Rivopam offers symptomatic relief for episodes of severe psychological distress. It is commonly used for the management of panic disorder to address symptom clusters that appear suddenly and create noticeable interference with daily stability. The anxiolytic benefit helps manage the intensity of recurrent panic attacks, including overwhelming fear and associated physical manifestations, which may support patients during difficult episodes.

Quick Fact: Relief for Acute Symptomatic Distress

Regulatory References

  1. MedlinePlus Drug Information Overview

Eligibility and Restrictions for Use

The official eligibility profile for Rivopam (Clonazepam) is defined by strict regulatory criteria regarding a patient’s pre-existing conditions, age, and organ function.

Contraindicated Populations

Use of Rivopam is strictly prohibited for patients with a documented sensitivity to clonazepam or any other benzodiazepine compound. The medicine is also contraindicated for patients with clinical evidence of significant liver disease or a diagnosis of acute narrow-angle glaucoma.

Regulatory documents further state that use is prohibited in cases of severe respiratory insufficiency and conditions such as sleep apnoea syndrome, or in patients diagnosed with Myasthenia gravis.

Age and Condition Restrictions

  • Pediatric Use: While approved for certain seizure disorders in children, the safety and efficacy for treating panic disorder are not established in patients under 18 years of age.
  • Older Adults: Geriatric patients must be started on lower doses and observed closely due to heightened sensitivity.
  • Hepatic/Renal Status: The medicine must be used with special caution in patients with renal impairment or mild to moderate hepatic impairment.
  • Pregnancy/Lactation: Use during late pregnancy may cause neonatal withdrawal symptoms. The drug is distributed into human milk, necessitating a decision by the regulatory authority on whether to discontinue the drug or nursing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Rivopam (Clonazepam) interaction patterns are officially documented by regulatory agencies and are primarily categorized by additive central nervous system (CNS) depressant effects and alterations to its metabolic clearance.

Documented Interaction Patterns

The most stringent caution is the co-administration with Opioids, a combination subject to a U.S. regulatory Boxed Warning due to the risk of profound sedation, severe respiratory depression, coma, and death. Use with Alcohol and other CNS depressant drugs, such as narcotics or antipsychotics, is advised against as it potentiates the depressant action of Clonazepam.

Interaction Type Interacting Substance Categories Regulatory Outcome
Pharmacokinetic (Metabolic) CYP3A4 Inducers (e.g., Carbamazepine) Reduction in Clonazepam concentration
Pharmacokinetic (Metabolic) CYP3A4 Inhibitors (e.g., Ketoconazole) Increase in Clonazepam serum concentration
Pharmacodynamic (Additive) CNS Depressants (including Alcohol) Potentiation of CNS depressant effects

Co-administration with the anti-convulsant Valproic Acid has been documented to produce a specific outcome known as absence status. Cautions exist for use in specific populations; for instance, impaired renal function creates a risk of metabolite accumulation, and the CNS depressant effects may be aggravated in individuals with pre-existing chronic pulmonary or hepatic impairment.

Mechanism of Action

Rivopam functions as a positive allosteric modulator of the GABA A receptor complex, which represents the major inhibitory neurotransmitter system within the central nervous system (CNS).

The molecule binds to a specific, high-affinity site on the interface of GABA A receptor subunits, distinct from the site where the native neurotransmitter, GABA, interacts. This binding induces a conformational change that increases the receptor's overall affinity for GABA, but does not directly activate the ion channel itself. The resulting enhancement increases the frequency of chloride ion ( Cl^-) channel openings upon GABA binding.

This increased Cl^- conductance drives a larger influx of negative ions across the neuronal membrane, leading to a state of hyperpolarization. This change in resting membrane potential decreases the neuron's ability to generate action potentials. The system-level physiological consequence of this intracellular cascade is a general reduction in neuronal excitability throughout the CNS.

Dosage and Administration Information

How Rivopam is Used

Rivopam is administered by the oral route and is available across multiple dosage forms, including the conventional tablet, the orally disintegrating tablet (ODT), and an oral solution. The medicine may be taken with or without food.


Official Dosing and Schedule Principles

The official labeling specifies a regimen of initial low doses followed by gradual, incremental increases. For adult seizure disorders, the typical starting dose is 1.5 mg per day, divided into two or three doses. This amount is then increased incrementally, generally by 0.5 mg to 1 mg every three days, until the required maintenance level is achieved, up to a maximum daily dose of 20 mg.

For panic disorder, the initial dose is lower, starting at 0.5 mg per day, usually divided into two administrations. A key timing principle states that if the total daily dose is not divided equally, the largest portion should be taken before retiring (at bedtime).


Administration Context and Tapering

Population-specific rules mandate starting with a lower initial dose for older adults (65 years and older) due to increased sensitivity. For pediatric patients (up to 10 years of age), initial dosing is calculated based on body weight (mg/kg/day). The oral solution must be measured with a calibrated device and may be mixed with certain non-alcoholic liquids, such as water or juice, before ingestion.

Continued use of the medication requires periodic reevaluation. When stopping, the drug must be gradually tapered according to a documented reduction protocol, as abrupt cessation is not permitted by official instructions.

Recent Clinical Evidence

Research evidence / Overview of studies for Rivopam (Clonazepam)


Evidence for Use in Severe Seizure Disorders

Research examining Rivopam for certain seizure disorders was derived from classic clinical trials and long-term observational settings. Studies monitored outcomes related to how symptoms change in populations including children experiencing conditions characterized by fluctuating manifestations, such as akinetic, myoclonic, and absence seizures, as well as symptoms related to Lennox-Gastaut syndrome. Outcomes focused on measurements of seizure frequency and severity.

Studies monitored outcomes related to symptom change in these groups, and regulatory review noted this potential for a diminished change in symptoms in a portion of patients, sometimes observed within the first three months of administration. What remains uncertain is the durability of the effect over extended periods, as follow-up durations were limited in the systematic, controlled settings.


Evidence for Use in Acute Panic Attacks and Intense Anxiety

The research base for Rivopam in managing acute symptomatic distress, such as panic disorder, relies on multiple short-term, randomized, double-blind, placebo-controlled studies (RCTs). This research was conducted to explore short-term symptom changes in adult outpatients. Studies monitored patient-reported outcomes describing perceived discomfort and measurements of episodic or acute changes like panic attack frequency.

The findings from these controlled trials, typically lasting six to nine weeks, describe patterns observed in the studied group compared to the comparison group. Research highlights changes measured during the study period, which was observed in studies focusing on conditions associated with acute or disruptive episodes.


Long-Term Research and the Durability of Effect

Research suggests follow-up durations were limited when exploring long-term outcomes, as data showing patterns related to the durability of the effect over periods extending beyond a few months come primarily from observational settings, not systematic, long-term RCTs. Therefore, long-term effects are not fully established through highly controlled research designs, meaning certainty remains low for outcomes over multiple years. Research is ongoing to provide more context regarding long-term use.

Key Studies & References

  1. Clonazepam in Panic Disorder: Efficacy and Mechanism of Action
  2. StatPearls: Clonazepam Pharmacology and Therapeutics (A standard clinical evidence summary)

Frequently Asked Questions (FAQ)

Common questions about Rivopam (FAQ)

Q: How quickly does Rivopam start working for panic attacks or anxiety symptoms?

According to official product information, the active ingredient in Rivopam is rapidly absorbed after being taken orally. It typically reaches its highest concentration in the bloodstream within one to four hours. The time to maximum concentration (Tmax) is a measure of how quickly the active ingredient is distributed in the body.


Q: Does taking Rivopam make you feel 'drugged' or impair cognitive function?

The official labeling describes several common adverse reactions that are characteristic of its central nervous system (CNS) activity. These effects include drowsiness (somnolence), dizziness, and impaired coordination (ataxia). These effects, particularly drowsiness and dizziness, are characteristic of the medication's central nervous system activity.


Q: Can Rivopam cause mood swings or changes in emotional response?

Regulatory documents include warnings about potential psychiatric disturbances and what are termed paradoxical reactions. These can involve changes in emotional response, such as increased agitation, aggression, hostility, irritability, and also feelings of depression or confusion.


Q: Does Rivopam interact with common over-the-counter pain relievers or cold medicines?

Official warnings caution against combining Rivopam with other medicines that cause central nervous system (CNS) depression. This means that taking the drug with sedating substances, including some common pain relievers or cold preparations, could potentially increase the effects of drowsiness and dizziness.


Q: Is Rivopam considered a controlled substance in the same category as other anxiety medicines?

Rivopam is classified as a Schedule IV federally controlled substance in the U.S. Controlled Substances Act. This classification is assigned because the medication has a recognized potential for abuse and physical dependence.


Q: How does Rivopam affect the central nervous system compared to non-benzodiazepine sedatives?

Rivopam is a benzodiazepine that works by enhancing the effects of the brain's main inhibitory chemical, called GABA. It binds to the GABA-A receptor complex, which reduces the overall excitability of nerve cells.


Q: What are the main findings from clinical trials regarding Rivopam's effectiveness for panic disorder?

Research supporting the use of Rivopam in panic disorder comes from short-term, controlled studies in adult outpatients. These studies monitored patient-reported outcomes, with findings related to the changes observed in the frequency of panic attacks during the trial period when compared to a placebo.


Q: Why do official sources recommend Rivopam mostly for short-term use?

Official documents note that some clinical research has recorded a potential loss of effect in a portion of patients, sometimes observed within the first three months of treatment. Because the durability of the effect over extended periods is not fully established through highly controlled research designs, certainty for long-term outcomes remains low.


Q: What is the main difference between Rivopam and other benzodiazepines like Xanax or Ativan?

Regulatory documents outline differences in the approved clinical uses for Rivopam compared to other medicines in its class. These drugs also differ in their onset of action (how quickly they start working) and their elimination half-life, which dictates how long the medicine stays active in the body.


Q: Does Rivopam affect memory, and is this a long-term concern?

Memory impairment is listed in the official documents as a potential adverse reaction of the medicine. Regulatory safety information notes that long-term exposure to benzodiazepines is associated with a risk of cognitive impairment.


Q: Can Rivopam affect blood pressure or heart rate?

While not listed as a common expected side effect, official documents on overdose note that hypotension (low blood pressure) may occur. Adverse reaction reports also include mentions of changes to the heart rate or pulse.


Q: Do official documents mention any connection between Rivopam and suicidal thoughts?

Regulatory safety information includes warnings that the medication has the potential to worsen depression and may cause thoughts of suicide or unusual changes in behavior. Official safety information indicates that patients should be monitored for sudden changes in mood or behavior.


Q: How long does Rivopam stay in the system after the last dose?

The elimination half-life of the active ingredient, Clonazepam, is typically between 30 and 40 hours. This measure describes the time it takes for the concentration of the medication in the body to decrease by half after the last dose.


Q: Why is grapefruit juice mentioned in warnings about taking Rivopam?

Official warnings state that consuming grapefruit or grapefruit juice may inhibit the body’s metabolism of the active ingredient. This action could potentially lead to exaggerated plasma concentrations of the medication in the bloodstream, increasing its effects.


Q: Is Rivopam used as a first-line treatment for its approved conditions?

Studies and official information indicate that for certain seizure disorders, Rivopam has often been used as an adjunct (additional) treatment alongside other drugs. It is also noted for its use in seizures that are refractory (unresponsive) to other anticonvulsant medications.


Q: What are the known potential interactions between Rivopam and herbal supplements?

Regulatory documents state that taking Rivopam with certain herbal remedies, especially those marketed for anxiety or insomnia, may potentially increase the drowsy or sedative effects of the medication.


Q: Are there specific symptoms that warrant calling a doctor immediately while taking Rivopam?

Regulatory patient information states that immediate medical attention is necessary if signs of a severe allergic reaction are observed. These signs include rash, hives, swelling of the face, tongue, or throat, or having difficulty breathing or swallowing.


Q: Are there any studies on Rivopam's use in patients with a history of substance abuse?

Regulatory documents include specific warnings regarding the risk of abuse, misuse, and addiction associated with this medicine. The official labeling notes that special caution is required when the medicine is used in patients with a history of alcohol or drug abuse.


Q: Can Rivopam cause unusual side effects like hair loss or increased appetite?

Official adverse reaction reports include mentions of less common side effects. These reports include instances of hair loss or thinning of the hair and experiencing an increased appetite.


Q: What happens if you accidentally miss a dose of Rivopam?

Regulatory patient information describes the general rule for a missed dose: it is typically to be taken as soon as remembered, unless the next dose is due shortly. Official guidance advises against taking a double dose to make up for a missed one.


Q: Are there any specific dietary restrictions associated with taking Rivopam?

According to official documents, while the medication can be taken with or without food, there is a specific caution regarding the consumption of grapefruit or grapefruit juice. Regulatory advice notes the importance of discussing this potential interaction with a healthcare provider.

How should Rivopam be stored and disposed of?

How to Store and Dispose of Rivopam?

Rivopam (clonazepam) tablets must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The official labeling requires the medication to be stored in a tight, light-resistant container and protected from moisture to maintain its stability.

Child-Safety Storage

It is a mandatory safety instruction to keep this medicine out of the reach of children.

Disposal Instructions

As a federally controlled substance (C-IV), unused or expired Rivopam must be disposed of following specific regulatory guidelines to prevent misuse. The preferred method is using a drug take-back program. If this option is unavailable, the medication must be mixed with an undesirable substance (such as dirt or coffee grounds) and placed into a sealed container before discarding it in the household trash. The medication is not on the list of drugs recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rivopam found in:

A-Z Index: